CGTN
23.3.2021 20:21:13 CET | Business Wire | Press release
Forestry reform, reform of the medical and healthcare system, and rural revitalization were highlighted in Chinese President Xi Jinping's second day of his inspection tour in east China's Fujian Province on Tuesday.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210323005995/en/
Visiting the Shaxian District of Sanming City on Tuesday, Xi went to an assets and equity exchange to learn about local efforts to deepen reform of the forest tenure system and a hospital to learn about local reform of the medical and healthcare system.
He also went to a village to inspect work on promoting rural revitalization.
'Lush mountains and lucid waters are valuable assets'
In the past, Chinese farmers were excluded from collective forestry and shared few timber revenues. As a result, they lacked the incentives to protect forests, and timber theft was rampant.
To solve these problems, Fujian Province launched the reform to decentralize the collective forest tenure system in favor of individual (household) management in 2003, which is also considered the start of China's new round of forest tenure reform.
It echoed Xi's instruction to develop forestry as an industry while maintaining its ecological functions when he worked in Fujian.
Xi had visited Sanming City 11 times when he worked in Fujian. During a trip to the city in June 2002, when he was Fujian governor, Xi emphasized that environmental development was of paramount importance.
He said at the time that it might seem that green mountains and lucid waters are of little value, but in the long term, they are valuable assets. He also urged local officials to transform economic growth and avoid wasting resources and damaging the environment.
To carry out Xi's instructions, local authorities further explored a number of reform measures, including taking steps to encourage farmers to transfer their timberland to forest cooperatives and other operators and issuing more loans to forestry businesses to solve their financial problems.
The total output value of forestry reached 114.6 billion yuan in 2019 in Sanming. The city's forest coverage is expected to exceed 80 percent in 2020.
Progress in the reform of the medical and healthcare system
Xi also visited the Shaxian General Hospital in Sanming City to learn about the local medical and healthcare system's reform.
Shaxian General Hospital has jurisdiction over 12 grass-roots branch hospitals and 128 extended village health clinics. Its establishment is also one of the measures to reform the local medical and health system.
Xi has paid close attention to the country's medical reform progress, and praised Sanming's medical advancement at several key meetings.
At the 33rd meeting of the central leading group for deepening overall reform on March 24, 2017, Xi hailed Sanming's experience in medical reform. He said Sanming's medical reform is in the right direction and has produced obvious results, urging promotion of Sanming's practice nationwide.
Shaxian snacks and rural revitalization
Xi has put forward ardent hopes for the development of Shaxian snacks many times, and on Tuesday, he visited the Yubang Village, which is famous for Shaxian snacks, to inspect work on promoting rural revitalization there.
Hailing from Shaxian, popular restaurant chain Shaxian Snacks is renowned for its pork wontons, peanut sauce noodles, and over 100 other local-flavor delicacies.
Starting with a single booth in a street market, the chain now has more than 88,000 chain stores in China and 62 other countries and regions, pulling in a hefty revenue exceeding 50 billion yuan ($7.6 billion).
Thus far, the Shaxian Snacks trademark has been approved by eight countries: Japan, New Zealand, Malaysia, Indonesia, the Philippines, South Korea, Singapore, and Australia. The Shaxian Snacks stores entered 62 countries, including the U.S., Germany, and Portugal. In three hours, the first store in New York sold out and sales revenue of the first store in Tokyo reached nearly $2,000 in 5 hours. After dominating China, it's now aiming at a bigger market and a brighter future.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323005995/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
